Curis Provides Fourth Quarter 2023 Business Update
Emavusertib data presented at ASH showed 3 of 5 patients achieved CR in R/R PCNSL
Expansion of clinical sites in US and Europe in progress
Cash runway into 2025
Related news for (CRIS)
- Curis Provides Second Quarter 2025 Business Update
- Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement
- Curis Provides Fourth Quarter 2024 Business Update
- Curis Announces Additional Data from TakeAim Leukemia Study
- curis announces $12.1 million registered direct and concurrent private placement